Correspondence 0001104659-23-090339 from NKGen Biotech, Inc. (NKGN, NKGNW) (CIK 0001845459)
NKGen Biotech, Inc. (NKGN, NKGNW) (CIK 0001845459)
Date: Aug. 11, 2023 · CIK: 0001845459 · Accession: 0001104659-23-090339
AI Filing Summary & Sentiment
File numbers found in text: 333-271929
Show Raw Text
CORRESP
1
filename1.htm
Graf Acquisition Corp. IV
1790 Hughes Landing Blvd., Suite 400
The Woodlands, Texas 77380
August 11, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jimmy McNamara and Alan Campbell
Re:
Graf Acquisition Corp. IV
Registration Statement on Form S-4
File No. 333-271929
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Graf Acquisition Corp. IV (the “Company”) hereby requests acceleration of the effective date
of the above referenced Registration Statement to 4:00 p.m., Eastern Time, on August 14, 2023, or as soon thereafter as practicable,
or at such other time as the Company or its outside counsel, White & Case LLP, request by telephone that such Registration Statement
be declared effective.
Please contact Elliott Smith of White &
Case LLP at (212) 819-7644 as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns
regarding this matter.
Sincerely,
/s/ James A. Graf
James A. Graf
Chief Executive Officer